StemSynergy Therapeutics

StemSynergy Therapeutics is a Miami-based biotechnology company founded in 2007, focused on the discovery and development of innovative small-molecule therapeutic agents targeting developmental signaling pathways fundamental to cancer. The company specializes in cancer stem cell (CSC) biology, developing novel modulators of the Wnt, Notch, and Myc signaling pathways that selectively ablate cancer stem/initiating cell populations with the goal of eliminating tumor growth. StemSynergy's breakthrough approach includes first-in-class agents with novel mechanisms of action and cellular targets that address previously intractable cancers including esophageal adenocarcinomas, colorectal cancers, triple-negative breast cancers, lung cancers, and sarcomas. The company has leveraged over 50 combined years of cancer research expertise from its four founders, who are faculty members at leading academic medical centers including the University of Miami Miller School of Medicine and UC San Francisco.